within Pharmacolibrary.Drugs.ATC.J;

model J01EA01_1
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 4.3333333333333334e-05,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0011,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00125,
    k12             = 3.8,
    k21             = 3.8
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01EA01_1</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Trimethoprim is an antibiotic that inhibits bacterial dihydrofolate reductase, interfering with folic acid synthesis required for bacterial DNA replication. It is commonly used, often in combination with sulfamethoxazole, for the treatment of urinary tract infections and a variety of other bacterial infections. Trimethoprim is a widely approved and routinely prescribed antimicrobial agent.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters after intravenous administration in healthy adults.</p><h4>References</h4><ol><li><p>Eyler, RF, &amp; Shvets, K (2019). Clinical Pharmacology of Antibiotics. <i>Clinical journal of the American Society of Nephrology : CJASN</i> 14(7) 1080–1090. DOI:<a href=\"https://doi.org/10.2215/CJN.08140718\">10.2215/CJN.08140718</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30862698/\">https://pubmed.ncbi.nlm.nih.gov/30862698</a></p></li><li><p>Nissenson, AR, et al., &amp; Holazo, A (1987). Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole during hemodialysis. <i>American journal of nephrology</i> 7(4) 270–274. DOI:<a href=\"https://doi.org/10.1159/000167484\">10.1159/000167484</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3500644/\">https://pubmed.ncbi.nlm.nih.gov/3500644</a></p></li><li><p>Cockerill, FR, &amp; Edson, RS (1991). Trimethoprim-sulfamethoxazole. <i>Mayo Clinic proceedings</i> 66(12) 1260–1269. DOI:<a href=\"https://doi.org/10.1016/s0025-6196(12)62478-1\">10.1016/s0025-6196(12)62478-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1749295/\">https://pubmed.ncbi.nlm.nih.gov/1749295</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01EA01_1;
